After the approval of the Covid-19 vaccine in India, the biggest vaccination campaign started and as of now, nearly 16 lakh people have been vaccinated. Moving forward in the same direction, there is a buzz that Tata Group’s healthcare venture is in the initial discussions with Moderna Inc of partnership to launch its Covid-19 vaccine in India.
There is a big possibility that the Tata Medical & Dignostics could team up with the India’s Council and Industrial Research to initialize the clinical trials of Morderna’s Vaccine in India as reported by the officals speculating about it.
Unlike Pfizer’s vaccine, which must be kept at minus 70 degrees Celsius or below, Moderna’s can be stored at normal fridge temperatures, making it more suited for poorer countries such as India where cold chains are limited.
Data released in November from Moderna’s late-stage study showed it was 94.1% effective with no serious safety concerns. The shot was approved for use in the United States in December and in Europe earlier this month.
It gave emergency-use approval to a vaccine by Bharat Biotech and state-run Indian Council of Medical Research and another licensed from Oxford University and AstraZeneca that is being produced by the Serum Institute.
India has the world’s second highest COVID-19 caseload after the United States, but daily cases have been declining since hitting a peak in September.
India’s drugs controller has said the overall efficacy of the AstraZeneca vaccine, locally branded COVISHIELD, was 70.42% based on trials done overseas, but the approval for Bharat Biotech’s COVAXIN has faced criticism due to the lack of efficacy data.
